ExodusPoint Capital Management LP Invests $568,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

ExodusPoint Capital Management LP purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,126 shares of the company's stock, valued at approximately $568,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after buying an additional 688,967 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after buying an additional 133,546 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock valued at $6,649,000 after acquiring an additional 95,547 shares during the last quarter. Norges Bank bought a new position in Kymera Therapeutics during the 4th quarter worth approximately $3,670,000. Finally, Geode Capital Management LLC increased its stake in Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after purchasing an additional 52,263 shares during the period.

Analyst Ratings Changes

Several research analysts recently commented on KYMR shares. Stephens reaffirmed an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Leerink Partners restated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. Finally, HC Wainwright raised their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.36.

Remove Ads

Kymera Therapeutics Stock Up 0.1 %

Shares of KYMR stock traded up $0.03 during mid-day trading on Tuesday, reaching $25.46. 412,126 shares of the company's stock traded hands, compared to its average volume of 549,140. The company's 50-day moving average price is $31.36 and its 200-day moving average price is $39.53. The company has a market cap of $1.65 billion, a P/E ratio of -10.88 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 over the last 90 days. Corporate insiders own 15.82% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.